DOR BioPharma, Inc., (OTCBB: DORB) ("DOR" or the "Company") announced today that it has entered into a Letter of Intent with Orphan Australia Pty Ltd. (Orphan Australia), a specialty pharmaceutical company based in Melbourne, Australia, pursuant to which Orphan Australia will act as DOR's Sponsor with regard to the administration of a Named Patient Access Program (NPAP) for orBec® to gastrointestinal Graft-versus-Host disease (GI GVHD) patients in Australia, New Zealand and South Africa.
